Everything you need to know about TMS in Children and Adolescents: FDA Guidelines, Safety, and Ethical Considerations — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Transcranial magnetic stimulation has transformed the treatment of several psychiatric and neurological conditions in adults, leading naturally to the question of whether the same benefits can be extended to children and adolescents. Pediatric populations represent a significant unmet need: major depressive disorder, OCD, and anxiety disorders frequently begin in childhood and adolescence, and the available treatment options — including medications with limited safety data in minors and psychotherapy that some children cannot or will not engage with — are inadequate for a substantial proportion of young patients. However, applying TMS to children and adolescents raises unique scientific, regulatory, ethical, and safety questions that deserve careful examination.

What You’ll Learn

• What the FDA’s age restrictions are for TMS by condition
• What the safety profile looks like for children and adolescents
• What the research shows about TMS for adolescent depression and pediatric OCD
• Important ethical considerations including informed assent
• What parents should know before pursuing TMS for their child

FDA Status and Age Restrictions

The FDA has established clear age restrictions on TMS devices, and these restrictions differ by indication:

For major depressive disorder (MDD): TMS devices are FDA-cleared only for adults age 18 and older. The FDA has specifically required that TMS not be used in patients younger than 18 for depression, based on the available safety data at the time of clearance.

For OCD: TMS is FDA-cleared for adults age 18 and older with OCD who have not responded to at least one medication.

For migraine: The FDA has cleared single-pulse TMS devices for the acute treatment of migraine with aura in adults. Pediatric use is not specifically addressed in the clearance.

For smoking cessation: FDA clearance applies to adults age 18 and older.

It is important to note that FDA clearance defines the conditions under which a device has been demonstrated to be safe and effective for its intended use. It does not prohibit off-label use entirely — physicians may prescribe FDA-cleared devices off-label based on their clinical judgment. However, off-label use of TMS in minors is a significant clinical and ethical decision that should only be made by specialists experienced in both pediatric neuromodulation and the condition being treated.

The Safety Profile in Children and Adolescents

TMS safety in pediatric populations is an active area of research, and the existing safety data are generally reassuring — but not as extensive as the adult data.

Seizure risk: The most serious potential adverse effect of TMS is the induction of a seizure. In adults, this risk is estimated at less than 1 in 30,000 sessions with standard protocols. In children, the seizure threshold is generally considered to be lower than in adults due to developmental differences in cortical excitability. However, with appropriate screening (excluding patients with epilepsy, structural brain lesions, or other seizure risk factors) and conservative dosing, the seizure risk appears to be very low in pediatric TMS studies. No seizures have been reported in the major pediatric TMS trials for depression and OCD to date.

Scalp discomfort and headache: These are the most common side effects in pediatric TMS and are similar in frequency and severity to what is observed in adults.

Hearing: The magnetic pulses produced by TMS generate a loud clicking sound. While brief exposure is considered safe, there is a theoretical concern about cumulative auditory risk, and pediatric patients typically wear ear protection during TMS sessions.

Cognitive and developmental effects: TMS does not appear to have negative cognitive effects in children. Some studies have even reported improvements in cognitive function following treatment. However, the long-term developmental implications of repeatedly modulating neural circuits during childhood and adolescence are not yet fully understood.

A 2022 comprehensive review published in Journal of Child Psychology and Psychiatry concluded that TMS is generally well-tolerated in children and adolescents when appropriate safety protocols are followed, with side effect rates comparable to or lower than those in adults. The review emphasized the importance of age-appropriate dosing, careful screening, and treatment by experienced clinicians.

What the Research Shows in Minors

Despite regulatory restrictions, significant research has been conducted on TMS in children and adolescents:

For adolescent depression: Several randomized controlled trials have investigated TMS in adolescents with treatment-resistant depression. A 2018 study published in Brain Stimulation found that 15 sessions of high-frequency left dlPFC TMS produced significant improvements in depression severity in adolescents (ages 12-21) who had failed at least one medication trial. The response rate was approximately 40% — comparable to adult response rates.

A larger, multisite trial of TMS in treatment-resistant adolescent depression was conducted and submitted to the FDA. While the results showed a signal of efficacy, the FDA did not extend clearance to adolescents based on the available evidence — citing the need for additional data.

For pediatric OCD: A randomized sham-controlled trial of TMS for pediatric OCD (ages 12-18) found that high-frequency TMS to the SMA produced significant improvements in Y-BOCS scores compared to sham treatment, with response rates of approximately 45% for active TMS versus 17% for sham. This study, published in Journal of the American Academy of Child and Adolescent Psychiatry, suggests that TMS may be particularly effective for adolescent OCD.

For pediatric anxiety and ADHD: Preliminary studies suggest TMS can reduce anxiety symptoms and improve attention in children and adolescents, but the evidence base is smaller and results more preliminary.

Ethical Considerations

Treating children and adolescents with TMS raises important ethical questions that clinicians and parents must carefully consider:

Informed assent: Children and adolescents should be involved in the treatment decision to the extent developmentally appropriate. This means explaining the treatment in age-appropriate terms, answering their questions honestly, and respecting their preferences. “Informed assent” — the child’s agreement to treatment — should be obtained alongside parental informed consent.

Long-term unknowns: The developing brain is in a state of active neuroplasticity. While TMS may theoretically enhance positive neuroplastic changes, the long-term effects of repeatedly modulating developing neural circuits are not yet known. This uncertainty should be transparently communicated to parents.

Limited alternatives: The ethical case for considering TMS in minors is strongest when the condition is severe, treatment-resistant, and significantly impairing — and when established alternatives (medications and psychotherapy) have been tried and found inadequate.

Vulnerability to marketing: Parents of children with serious psychiatric conditions are understandably desperate for effective treatments. The enthusiasm of some providers and the desperation of some families must not override careful scientific and ethical evaluation.

What Parents Should Know

For parents considering TMS for their child:

1. Start with established treatments first: CBT/ERP and FDA-approved medications for your child’s specific condition should be the first-line approach.
2. Seek experienced specialists: TMS for children and adolescents should only be provided by clinicians with specific training and experience in pediatric neuromodulation.
3. Understand the regulatory status: TMS for depression is not FDA-cleared for anyone under 18. Off-label use may be clinically appropriate in some cases, but you should be fully informed about the evidence and the unknowns.
4. Look for clinical trials: Clinical trials provide access to TMS under carefully controlled research conditions, with close monitoring and institutional review board oversight.
5. Get multiple opinions: Before proceeding with any treatment for your child, especially an off-label one, consult with multiple qualified specialists.

The field of pediatric TMS is evolving rapidly, and it is likely that future FDA clearances will expand to include adolescent populations as the evidence base grows. In the meantime, careful, ethical, evidence-informed application of TMS to minors in specialized settings offers a pathway to relief for the most treatment-resistant young patients.